Cargando…

Predictive Factors for Level V Lymph Node Metastases in Papillary Thyroid Carcinoma with BRAF(V600E) Mutation and Clinicopathological Features

BACKGROUND: Therapeutic lateral neck dissection (LND) is recommended in papillary thyroid carcinoma (PTC) patients with clinically lateral lymph node metastasis (LLNM), whether underwent level V LND remains controversial for lacking of sensitive predicting system. BRAF(V600E) mutation is associated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Gui-you, Tan, Hai-long, Chen, Pei, Hu, Hui-Yu, Liu, Mian, Ou-yang, Deng-jie, Khushbu, Rooh-afza, Pun, Deepak, Li, Jin-dong, Zhang, Zhi-peng, Yang, Qiong, Huang, Peng, Chang, Shi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231772/ https://www.ncbi.nlm.nih.gov/pubmed/32494201 http://dx.doi.org/10.2147/CMAR.S247914

Ejemplares similares

Preoperative Sonographic and Clinicopathological Predictors for Solitary Lateral Neck Node Metastasis in Papillary Thyroid Carcinoma: A Retrospective Study
por: Yang, Qiong, et al.
Publicado: (2020)

BRAF V600E and lymph node metastases in papillary thyroid cancer
por: Chen, Pan, et al.
Publicado: (2020)

Sacral metastases in a patient with BRAF V600E+ papillary thyroid carcinoma
por: Bhethanabotla, Rohith M, et al.
Publicado: (2023)

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors
por: Choi, Sun Yi, et al.
Publicado: (2013)

Association between BRAF(V600E) mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma
por: Lu, Hai-Zhen, et al.
Publicado: (2017)

Comprehensive Analysis of Prognostic Alternative Splicing Signature Reveals Recurrence Predictor for Papillary Thyroid Cancer
por: Liu, Mian, et al.
Publicado: (2021)

Integrating BRAF(V600E) mutation, ultrasonic and clinicopathologic characteristics for predicting the risk of cervical central lymph node metastasis in papillary thyroid carcinoma
por: Zhang, Zheng, et al.
Publicado: (2022)

High Preponderance of BRAF V600E Mutation in Papillary Thyroid Carcinoma Among Filipinos: A Clinicopathologic Study
por: Espiritu, Gerard Anthony M., et al.
Publicado: (2019)

Deep Small RNA Sequencing of BRAF V600E Mutated Papillary Thyroid Carcinoma With Lymph Node Metastasis
por: Yusof, Azliana Mohamad, et al.
Publicado: (2019)

The Association of BRAF V600E Mutation With Tissue Inhibitor of Metalloproteinase-3 Expression and Clinicopathological Features in Papillary Thyroid Cancer
por: Zarkesh, Maryam, et al.
Publicado: (2018)

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China
por: Huang, Meiling, et al.
Publicado: (2019)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

Predicting factors of central lymph node metastasis and BRAF(V600E) mutation in Chinese population with papillary thyroid carcinoma
por: Zhou, Sheng Li, et al.
Publicado: (2021)

Associations of the BRAF(V600E) Mutation with Sonographic Features and Clinicopathologic Characteristics in a Large Population with Conventional Papillary Thyroid Carcinoma
por: Park, Ah Young, et al.
Publicado: (2014)

Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAF(V600E) Mutational Status and Expression of Angiogenic Factors
por: Shi, Chenlei, et al.
Publicado: (2016)

BRAF(V600E) mutation, BRAF-activated long non-coding RNA and miR-9 expression in papillary thyroid carcinoma, and their association with clinicopathological features
por: Shi, Chenlei, et al.
Publicado: (2020)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma
por: Yan, Changjiao, et al.
Publicado: (2019)

Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wei, Xiaojing, et al.
Publicado: (2022)

The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma
por: Scheffel, Rafael Selbach, et al.
Publicado: (2020)

BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account
por: Dong, Si-Yang, et al.
Publicado: (2017)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Coexisting Germline CHEK2 and Somatic BRAF(V600E) Mutations in Papillary Thyroid Cancer and Their Association with Clinicopathological Features and Disease Course
por: Gąsior-Perczak, Danuta, et al.
Publicado: (2019)

Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series
por: Pessôa-Pereira, Danielle, et al.
Publicado: (2019)

Papillary thyroid cancer organoids harboring BRAF(V600E) mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
por: Chen, Dong, et al.
Publicado: (2023)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Prevalence of BRAF(V600E) Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAF(V600E) Prevalent Area
por: Kim, Hyereen, et al.
Publicado: (2018)

Clinicopathological Significance of BRAF(V600E) Mutation in Colorectal Cancer: An Updated Meta-Analysis
por: Wang, Jianhua, et al.
Publicado: (2019)

BRAF(V600E) Mutant Allele Frequency (MAF) Influences Melanoma Clinicopathologic Characteristics
por: Soria, Xavier, et al.
Publicado: (2021)

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

Correlation between Ultrasonographic Appearance of Papillary Thyroid Microcarcinoma and BRAF V600E Mutation
por: Liang, Songnian, et al.
Publicado: (2022)

Comparative BRAF V600E immunohistochemical expression in differentiated thyroid tumors with papillary features
por: Wahid, Maha Hatem Abdul, et al.
Publicado: (2022)

Association between BRAF(V600E) mutation and the clinicopathological features in incidental papillary thyroid microcarcinoma: A single-center study in Turkish patients
por: Sezer, Havva, et al.
Publicado: (2020)

Co-existence of BRAF(V600E) and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis
por: Ren, Haoyu, et al.
Publicado: (2018)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Integrating US-guided FNAB, BRAF(V600E) mutation, and clinicopathologic characteristics to predict cervical central lymph-node metastasis in preoperative patients with cN0 papillary thyroid carcinoma
por: Ma, Ning, et al.
Publicado: (2023)

A Prediction Model for Contralateral Central Neck Lymph Node Metastases in Unilateral Papillary Thyroid Cancer
por: Tan, Hai-Long, et al.
Publicado: (2021)

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_n2mv3oub192g2qihihv31ohqor